Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$25M
- −117.2% YoY · −12.7% QoQ
- EPS (diluted)
- −$1.71
- −66.0% YoY · −11.0% QoQ
Source: XBRL data from the PALVELLA THERAPEUTICS, INC. (PVLA) Q3 2026 10-Q on SEC EDGAR. USD.
PALVELLA THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue, consistent with no commercial revenue or operating cash flows expected near-term
- Net loss $24.6M vs $11.3M YoY, operating loss $22.7M vs $10.2M
- R&D expense $10.8M vs $6.5M YoY, G&A expense $11.9M vs $3.6M
- Cash and short-term investments $236.7M, operating cash outflow $38.1M, financing inflow $216.5M
- FDA Priority Review, PDUFA date February 28, 2027, planned U.S. launch first half of 2027 if approved
Risk Factors
- No material changes reported from the 2025 Form 10-K
- Financing risk: securities investment involves a high degree of risk
- Disclosure risk: quarterly results require review alongside MD&A and unaudited financial statements
- Carried-forward risks: 2025 Form 10-K risk factors remain applicable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PALVELLA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.